GSK Gets Chance For Input Into EU's Avandia Deliberations
Executive Summary
GlaxoSmithKline will have a chance to answer some further questions from the EU's drug advisory panel before it develops a recommendation later this month on the marketing authorization for GSK's diabetes therapy Avandia (rosiglitazone).